Refractory livedoid vasculopathy successfully treated with baricitinib

Int J Dermatol. 2023 Sep;62(9):1204-1205. doi: 10.1111/ijd.16467. Epub 2022 Nov 8.

Authors

Yue Xiao^#¹, Yiyi Wang^#¹, Yuanxia Gu¹, Dengmei Xia^{1

2}, Wei Li¹

Affiliations

¹ Department of Dermatology and Venereology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
² Department of Dermatology, The Affliated Hospital of Southwest Medical University, Luzhou, China.

^# Contributed equally.

PMID: 36349427
DOI: 10.1111/ijd.16467

No abstract available

Publication types

Letter
Comment

MeSH terms

Azetidines* / therapeutic use
Humans
Livedo Reticularis*
Purines / therapeutic use
Pyrazoles / therapeutic use

Substances

baricitinib
Azetidines
Purines
Pyrazoles

Grants and funding